News & Press Releases
Filter by:
Law Firms Caught in Balancing Act Between Repopulating Offices and Future of Remote Work
August 11, 2021
In an article published by The American Lawyer, Mintz Managing Member Bob Bodian was quoted among several law firm leaders on how they are working to safely reopen offices and, at the same time, planning for the future of remote work.
Peloton Tested a U.S. Safety Watchdog. It Wasn’t the First.
August 10, 2021
Mintz Member and Co-chair of the firm’s Retail and Consumer Products Practice Chuck Samuels was quoted in an article published by The Wall Street Journal on the Consumer Product Safety Commission (CPSC)’s recall request on Peloton treadmills. Specifically, Mr. Samuels discussed how the CPSC’s protocols prevent government overreach and allow companies to comment on the accuracy of recall disclosures.
4 Tips For Handling Religious Objections To Vaccine Mandates
August 10, 2021
Mintz Member Jennifer B. Rubin was quoted in an article published by Law360’s Employment Authority that provided employers with tips on handling religious objections to COVID-19 vaccine mandates, including keeping vaccination discussions private, vaccine education, and more.
Mintz Member Tara Dwyer was quoted in a Bloomberg Government article on the passage of the bipartisan infrastructure package and reconciliation bill, which would be paid for in part by delaying a controversial rebate rule – a rule which pharmacy benefit managers and insurers are in stiff opposition to.
Mintz Member Anne Levin-Nussbaum authored an article published by Tax Notes explaining how foreign investors in U.S. renewables projects might determine how much debt to use when capitalizing a U.S. blocker corporation.
1st Circuit Tightens Lid on Investor Suits
August 6, 2021
Massachusetts Lawyers Weekly reported on a recent decision by the 1st U.S. Circuit Court of Appeals in Karth v. Keryx Biopharmaceuticals Inc., which said a Keryx Biopharmaceuticals Inc. investor cannot revive his lawsuit alleging the Boston-based pharmaceutical company hid supply chain issues. Mintz Member Laurence A. Schoen, who represented the biopharma company, discussed how the decision closes the door on ‘fraud by hindsight’ claims.
Press Contact